Amisulpride - Acacia Pharma

Drug Profile

Amisulpride - Acacia Pharma

Alternative Names: APD-403; APD-421; BAREMSIS®; BARHEMSYS

Latest Information Update: 01 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acacia Pharma
  • Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative nausea and vomiting
  • Phase II Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Postoperative-nausea-and-vomiting(In volunteers) in Japan (IV, Injection)
  • 11 Jul 2018 Acacia Pharma plans a phase I trial for Chemotherapy induced nausea and vomiting (In volunteers, Monotherapy, Combination therapy) (IV) (NCT03583489)
  • 09 Jul 2018 Acacia Pharma plans to launch amisulpride for Post-operative nausea and vomiting in USA in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top